Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0025202 (melanoma)
 69,561 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

A case is presented of a 55-year-old woman with fever, cough, chest pain, and hemoptysis. A chest x-ray showed a large mass in the right upper lobe of the lung. Bronchoscopy and bronchial biopsies revealed malignant melanoma of the bronchus. Careful search of all common sites for melanoma and the histological examinations of the two skin lesions failed to substantiate the possibility of an extrapulmonary origin and, thus, by deduction it can be assumed with some certainty that this lesion is primary bronchial melanoma.Total pneumonectomy, when there is no evidence of extrapulmonary extension, coupled with adjuvant chemotherapy seem to offer a chance of cure.The patient presented is the first reported case of primary malignant melanoma of the bronchus from the University College Hospital, Ibadan, and perhaps the first reported case in a Nigerian.
 ...
PMID:Primary malignant melanoma of the bronchus. 48 Mar 95

Trimetrexate glucuronate (TMTX) is a methotrexate (MTX) analog that is active against transport-deficient MTX-resistant tumor cells. We performed a phase I study of TMTX administered by daily bolus for 9 consecutive days since this schedule is one of the most active in experimental murine tumor models. The drug was administered in this fashion every 4 weeks for at least two cycles. Fifteen patients with refractory metastatic cancers were studied and all had received prior chemotherapy. The dose-limiting toxicity was a rapidly reversible thrombocytopenia first seen at a daily dose of 4.0 mg/m2 which occurred 7 days after the end of TMTX administration. There was great inter- and intrapatient variability in the platelet nadirs observed in the six patients treated at 4.0 mg/m2. One patient died of massive hemoptysis during a platelet nadir at that dose level. Granulocyte counts never dropped below 1500/mm3. Only one patient had significant non-hematological toxicity: a radiation recall skin toxicity along with a self-limited maculopapular rash. One patient with melanoma and lung metastases treated at 4.0 mg/m2 had a partial response. TMTX plasma levels were measured by HPLC every 3 days prior to daily dosing in patients receiving 4 mg/m2 to determine whether drug accumulation occurred during this prolonged administration schedule. Nadir drug levels varied from less than 0.02 to 0.35 microM and did not seem to increase during the 9-day schedule in individual patients. By comparison with other phase I trials, the hematologic toxicity of TMTX seems to be schedule-dependent, with less drug being tolerated and more severe thrombocytopenia observed with more protracted treatment protocols. A firm phase II starting dose for daily bolus X 9 schedules is difficult to recommend in view of the variable toxicity observed in the patients treated at 4.0 mg/m2 daily, who, in addition, had all been extensively pretreated. A reasonable starting dose might be 3.0 mg/m2 daily with built-in dosage increases or decreases.
 ...
PMID:A phase I study of trimetrexate, an analog of methotrexate, administered monthly in the form of nine consecutive daily bolus injections. 295 89

This case concerns a 48 year-old patient whose endobronchial malignant melanoma was discovered on the occasion of a haemoptysis. A search for primary localization remained negative, suggesting a primary endobronchial lesion. Only a few cases of endobronchial malignant melanoma have been published, and several assumptions can be raised to explain the possibility of their primary origin.
 ...
PMID:[Malignant endobronchial melanoma, apparently primary. Apropos of a case]. 305 64

A case of primary bronchial malignant melanoma occurred in a 66 years old woman is reported. Because of cough and hemoptysis bronchoscopic examination was performed and and a polypoid mass was found to occlude the right lower bronchus. Histopathologic examination showed the presence of malignant melanoma also confirmed by immuno reactivity with antibodies to S-100 protein and melanoma associated monoclonal antibody HMB45. Clinical history, physical examination and other instrumental investigations failed to find other possible primary sites of the tumour. Primary melanoma of the lung is a very rare condition, but our case seems to satisfy the criteria to be considered in the little group of definite primary melanoma of the lower respiratory tract.
 ...
PMID:Primary bronchial malignant melanoma. A case report. 773 83

Endobronchial metastasis (EM) from nonpulmonary tumors is uncommon. A 9-year retrospective study at the University Hospital Vall d'Hebron (Barcelona, Spain) identified 32 patients with EM. All but four cases were diagnosed by fiberoptic bronchoscopy with bronchial biopsy. Primary tumors included the following types: breast cancer (20), colorectal cancer (3), melanoma (2), gastric cancer (1), neuroblastoma of the olfactory nerve (1), abdominal leiomyosarcoma (1), hypernephroma (1), endometrial carcinoma (1), papillary thyroid cancer (1), and hepatocarcinoma (1). Median age at diagnosis of EM was 58.7 years and median interval from the diagnosis of the primary tumor to the diagnosis of EM was 50.4 months. Seventeen patients (53%) had evidence of other metastatic sites at endobronchial relapse. The more common clinical manifestations included cough (37.5%), haemoptysis (28%), dyspnea (18.7%), and recurrent pulmonary infections (6.2%). Eight patients (25%) had no symptoms. There appears to be a predilection for metastatic involvement of the right and left upper lobe bronchus. Treatment was instituted in 20 patients, and their median survival was 11 months, in comparison with the 3 months found in 12 patients who received only palliative therapy because of advanced disseminated disease. Breast cancer is the most common tumor causing EM. The prognosis of patients with EM depends on the type of the primary tumor and the presence of other metastatic sites. Treatment must be individualized.
 ...
PMID:Endobronchial metastatic disease: analysis of 32 cases. 869 37

Primary pulmonary melanoma is a very rare disease, with only 19 cases previously reported in the English language literature. These cases suggest that melanoma can arise in the lung as a primary tumor, probably from residual melanoblasts. Primary pulmonary melanoma is frequently endobronchial and often manifests with symptoms of cough, hemoptysis, and lobar collapse. Aggressive surgical resection, irrespective of lymph node involvement, offers possible long-term survival in some patients. The diagnosis of primary pulmonary melanoma necessitates that both clinical and histologic criteria be fulfilled. Herein diagnostic criteria are proposed, and the diagnostic approach is discussed.
 ...
PMID:Primary pulmonary melanoma: case report and literature review. 998 35

Primary pulmonary melanoma is a rare disease, and only 20 cases have been published previously in the English literature. A 44-year-old woman presented initially with haemoptysis, and a chest roentgenogram showed a single lung mass. The diagnosis of primary pulmonary melanoma necessitates reliance on both clinical and histological criteria. The image of endobronchial ultrasonography (EBUS) in our case was not distinct from the image of lung cancer.
Melanoma Res 2005 Jun
PMID:Primary pulmonary malignant melanoma presenting with haemoptysis. 1591 6

Endobronchial metastases (EBM) from extrapulmonary malignant tumors are rare. The most common extrathoracic malignancies associated with EBM are breast, renal and colorectal carcinomas. In this study, we aimed to evaluate the clinical, radiographic and bronchoscopic aspects of patients with EBM who were diagnosed between 1992 and 2002. Data about patients' clinical conditions, symptoms, radiographic and endoscopic findings, and histopathological examination results were investigated. EBM was defined as bronchoscopically visible lesions histopathologically identical to the primary tumor in patients with extrapulmonary malignancies. We found 15 cases with EBM. Primary tumors included breast (3), colorectal (3), and renal (2) carcinomas; Malignant Melanoma (2); synovial sarcoma (1), ampulla of Vater adenocarcinoma (1), pheochromocytoma (1), hypernephroma (1), and Hodgkin's Disease (1). The most common symptoms were dyspnea (80%), cough (66.6%) and hemoptysis (33.3%). Multiple (40%) or single (13.3%) pulmonary nodules, mediastinal or hilar lymphadenopathy (40%), and effusion (40%) were the most common radiographic findings. The mean interval from initial diagnosis to diagnosis of EBM was 32.8 months (range, 0-96 months) and median survival time was 18 months (range, 4-84). As a conclusion, various extrapulmonary tumors can metastasize to the bronchus. Symptoms and radiographic findings are similar with those in primary lung cancer. Therefore, EBM should be discriminated from primary lung cancer histopathologically. Although mean survival time is usually short, long-term survivors were reported. Consequently, treatment must be planned according to the histology of the primary tumor, evidence of metastasis to other sites and medical status of the patient.
 ...
PMID:Endobronchial metastases from extrathoracic malignancies. 1647 29

We report a rare case of a primary melanoma of the lung initially presenting with haemoptysis, which was diagnosed using 2 new immunohistochemistry markers and cytology with immunocytochemistry. A 67-year-old male underwent repeated major lung resections and died because of early recurrences of a primary pulmonary melanoma as detailed study excluded other primary foci. The diagnosis of the patient's last recurrence was achieved on a fine needle aspiration (FNA) specimen with immunocytochemistry. To the best of our knowledge this is the first case of primary pulmonary melanoma diagnosed by immunocytochemistry on FNA material.
 ...
PMID:Primary pulmonary melanoma diagnosis: the role of immunohistochemistry and immunocytochemistry. 1806 15

Tracheal melanomas represent the rarest type of extracutaneous melanomas. The clinical manifestation is similar to other tracheal tumors and ranges from symptoms of airway obstruction such as dyspnea and stridor to other nonspecific symptoms such as hoarseness, cough and hemoptysis. Bronchoscopy is required to draw the origin of the lesion biopsy is needed to establish histologic diagnosis. Treatment consists of either palliative surgery aiming at restoring the airway or tracheal resection and end to end anastmosis. We would like to present here below a rare case of tracheal melanoma and discuss the various diagnostic and therapeutic means.
 ...
PMID:Primary malignant melanoma of the trachea. 2039 66


1 2 3 Next >>